Everett Crosland

Chief Commercial Officer at Cognito Therapeutics

Everett leads the commercial organization at Cognito Therapeutics, a pioneer in neuromodulation to treat neurodegenerative. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and initiated a pivotal, phase 3 study in December, 2022. As Chief Commercial Officer, Everett leads Cognito's commercial readiness, marketing, sales, and health economic evidence development for the company’s breakthrough treatment portfolio. Everett was previously CCO at AppliedVR and VP of Market Access, Reimbursement & Government Affairs at Pear Therapeutics.